Upload Avatar (500 x 500)
Bo Zhu
Basic Medical Sciences
Chongqing Medical University
Chongqing
Language: English, Chinese
Tumor
Immunology
Cancer
Therapy
Cells
Molecular
Mechanism
Regulation
Precision
Treatment
Areas of Focus
- Tumor Immunology
Work Experience
- 2003.07-2005.07 - Third Military Medical University Second Affiliated Hospital - Attending Physician, Lecturer
- 2005.07-2007.12 - Queen Mary University of London - Postdoctoral Researcher
- 2005.07-2008.12 - Third Military Medical University Second Affiliated Hospital - Associate Professor, Associate Chief Physician
- 2008.12-2012.06 - Third Military Medical University Second Affiliated Hospital - Deputy Director, Professor, Doctoral Supervisor
- 2012.06-present - Army Medical University Second Affiliated Hospital - Director, Professor, Doctoral Supervisor
Academic Background & Achievements
- 1992.09-1997.07 Bachelor's Degree in Clinical Medicine: Third Military Medical University
- 1997.09-2000.07 Master's Degree in Experimental Hematology: Third Military Medical University
- 2000.09-2003.07 Doctorate in Oncology: Third Military Medical University
- Published over 100 papers in international journals, with 25 papers having an impact factor greater than 10
- Authored/Co-authored 3 monographs and 11 clinical guidelines
- Received National Natural Science Second Prize, Chongqing Natural Science First Prize, Chongqing Science and Technology Progress Second Prize, Chinese Medical Science and Technology Progress First Prize, and Ministry of Education Natural Science Second Prize
Publications
- Tumor-associated myeloid cells in cancer immunotherapy, Cheng X, Wang H, Wang Z, Zhu B*, Long H*, 2023
- CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy, Xinxin Wang#, Haoran Zha#, Wei Wu, Ting Yuan, Shuanglong Xie, Zheng Jin, Haixia Long, Fei Yang, Zhongyu Wang, Anmei Zhang, Jianbao Gao, Ying Jiang, Lujing Wang, Chunyan Hu, Yisong Y. Wan, Qi-Jing Li, Alistair L.J. Symonds, Qingzhu Jia*, Bo Zhu*, 2023
- Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy, Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, Hu C, Wang X, Zhang J, Ba Y, Gong Y, Zeng X, Zeng D, Su X, Alexander PB, Wang L, Wang L, Wan YY, Wang XF, Zhang L, Li QJ, Zhu B, 2022
- High-throughput single-сell sequencing in cancer research, Jia Q, Chu H, Jin Z, Long H*, Zhu B*, 2022
- Modulating tumor physical microenvironment for fueling CAR-T cell therapy, Luo Z, Yao X, Li M, Fang D, Fei Y, Cheng Z, Xu Y*, Zhu B*, 2022
- Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing During Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer, Jia Q, Chiu L, Wu S, Bai J, Peng L, Zheng L, Zang R, Li X, Yuan B, Gao Y, Wu D, Li X, Sun J*, He L, Robinson B, Zhu B*, 2020
- Transformation to Lung Adenocarcinoma From Complete Remission-Experienced SCLC, Wang Z, Jia Q, Tang X, Yan L, Zhu B*, 2020
- The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection, Chen X#, Cao G#, Wu J#, Wang X#, Pan Z, Gao J, Tian Q, Xu L, Li Z, Hao Y, Huang Q, Wang P, Xiao M, Xie L, Tang S, Liu Z, Hu L, Tang J, He R, Wang L, Zhou X, Wu Y, Chen M, Sun B, Zhu B*, Huang J*, Ye L*, 2020
- Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients with Lung Adenocarcinoma, Gong Z#; Jia Q#; Chen J; Diao X; Gao J; Wang X; Zhu B*, 2019
- Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation, Zhou J#, Huang S#, Wang Z#, Huang J, Xu L, Tang X, Wan YY, Li QJ, Symonds ALJ, Long H*, Zhu B*, 2019
- Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells, Zhao L#; He R#; Long H#; Guo B#; Jia Q; Qin D; Liu SQ; Wang Z; Xiang T; Zhang J; Tan Y; Huang J; Chen J; Wang F; Xiao M; Gao J; Yang X; Zeng H; Wang X; Hu C; Alexander PB; Symonds ALJ; Yu J; Wan Y; Li QJ*; Ye L* Zhu B*, 2018
- Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer, Jia Q#; Wu W#; Wang Y; Alexander PB; Sun C; Gong Z; Cheng JN; Sun H; Guan Y; Xia X; Yang L; Yi X; Wan YY; Wang H; He J; Futreal PA; Li QJ*, Zhu B*, 2018
- C5aR, TNF-α, and FGL2 contribute to coagulation and complement activation in virus-induced fulminant hepatitis, Liu J(#); Tan Y(#); Zhang J(#); Zou L; Deng G; Xu X; Wang F; Ma Z; Zhang J; Zhao T; Liu Y; Li Y; Zhu B(*); Guo B(*), 2015
Awards
- National Natural Science Second Prize: Detail
- Chongqing Natural Science First Prize: Detail
- Chongqing Science and Technology Progress Second Prize: Detail
- Chinese Medical Science and Technology Progress First Prize: Detail
- Ministry of Education Natural Science Second Prize: Detail
